Neuroprotective Effects of GH625-lipoPACAP in an In Vitro Fluid Dynamic Model of Parkinson's Disease

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Oct 27

PMID 36289905

Authors

Teresa Barra

Annarita Falanga

Rosa Bellavita

Jessica Pisano

Vincenza Laforgia

Marina Prisco

Stefania Galdiero

Salvatore Valiante

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is an aggressive and devastating age-related disorder. Although the causes are still unclear, several factors, including genetic and environmental, are involved. Except for symptomatic drugs, there are not, to date, any real cures for PD. For this purpose, it is necessary develop a model to better study this disease. Neuroblastoma cell line, SH-SY5Y, differentiated with retinoic acid represents a good in vitro model to explore PD, since it maintains growth cells to differentiated neurons. In the present study, SH-SY5Y cells were treated with 1-methyl-4-phenylpyridinium (MPP), a neurotoxin that induces Parkinsonism, and the neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP), delivered by functionalized liposomes in a blood-brain barrier fluid dynamic model, were evaluated. We demonstrated PACAP neuroprotective effects when delivered by gH625-liposome on MPP-damaged SH-SY5Y spheroids.

Citing Articles

Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system.

Luo Q, Yang J, Yang M, Wang Y, Liu Y, Liu J Mater Today Bio. 2025; 31:101457.

PMID: 39896289 PMC: 11786670. DOI: 10.1016/j.mtbio.2025.101457.

Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer.

Bellavita R, Piccolo M, Leone L, Ferraro M, Dardano P, De Stefano L Int J Nanomedicine. 2024; 19:6057-6084.

PMID: 38911501 PMC: 11193445. DOI: 10.2147/IJN.S453958.

An Overview of Supramolecular Platforms Boosting Drug Delivery.

Bellavita R, Braccia S, Falanga A, Galdiero S Bioinorg Chem Appl. 2023; 2023:8608428.

PMID: 38028018 PMC: 10661875. DOI: 10.1155/2023/8608428.

References

Ito K, Eguchi Y, Imagawa Y, Akai S, Mochizuki H, Tsujimoto Y . MPP+ induces necrostatin-1- and ferrostatin-1-sensitive necrotic death of neuronal SH-SY5Y cells. Cell Death Discov. 2017; 3:17013. PMC: 5327502. DOI: 10.1038/cddiscovery.2017.13. View

Xicoy H, Wieringa B, Martens G . The SH-SY5Y cell line in Parkinson's disease research: a systematic review. Mol Neurodegener. 2017; 12(1):10. PMC: 5259880. DOI: 10.1186/s13024-017-0149-0. View

Botia B, Jolivel V, Burel D, Le Joncour V, Roy V, Naassila M . Neuroprotective effects of PACAP against ethanol-induced toxicity in the developing rat cerebellum. Neurotox Res. 2010; 19(3):423-34. DOI: 10.1007/s12640-010-9186-y. View

Poujol de Molliens M, Jamadagni P, Letourneau M, Devost D, Hebert T, Patten S . Design and biological assessment of membrane-tethering neuroprotective peptides derived from the pituitary adenylate cyclase-activating polypeptide type 1 receptor. Biochim Biophys Acta Gen Subj. 2019; 1863(11):129398. DOI: 10.1016/j.bbagen.2019.07.007. View

Lopes F, Schroder R, da Frota Jr M, Zanotto-Filho A, Muller C, Pires A . Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies. Brain Res. 2010; 1337:85-94. DOI: 10.1016/j.brainres.2010.03.102. View

Iachetta G, Falanga A, Molino Y, Masse M, Jabes F, Mechioukhi Y . gH625-liposomes as tool for pituitary adenylate cyclase-activating polypeptide brain delivery. Sci Rep. 2019; 9(1):9183. PMC: 6591382. DOI: 10.1038/s41598-019-45137-8. View

Fang Y, Shi H, Ren R, Huang L, Okada T, Lenahan C . Pituitary Adenylate Cyclase-Activating Polypeptide Attenuates Brain Edema by Protecting Blood-Brain Barrier and Glymphatic System After Subarachnoid Hemorrhage in Rats. Neurotherapeutics. 2020; 17(4):1954-1972. PMC: 7851266. DOI: 10.1007/s13311-020-00925-3. View

Douiri S, Bahdoudi S, Hamdi Y, Cubi R, Basille M, Fournier A . Involvement of endogenous antioxidant systems in the protective activity of pituitary adenylate cyclase-activating polypeptide against hydrogen peroxide-induced oxidative damages in cultured rat astrocytes. J Neurochem. 2016; 137(6):913-30. DOI: 10.1111/jnc.13614. View

Burks S, Raymick J, Robinson B, Hanig J, Sarkar S . Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson's disease mouse model: Endothelial and microglial effects. Neurosci Lett. 2019; 703:86-95. DOI: 10.1016/j.neulet.2019.03.015. View

10.

Lesage S, Brice A . Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009; 18(R1):R48-59. DOI: 10.1093/hmg/ddp012. View

11.

Kovalevich J, Langford D . Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods Mol Biol. 2013; 1078:9-21. PMC: 5127451. DOI: 10.1007/978-1-62703-640-5_2. View

12.

Waschek J . VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair. Br J Pharmacol. 2013; 169(3):512-23. PMC: 3682700. DOI: 10.1111/bph.12181. View

13.

Sundrum T, Walker C . Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine. Br J Pharmacol. 2017; 175(21):4109-4120. PMC: 6177619. DOI: 10.1111/bph.14053. View

14.

Liao C, de Molliens M, Schneebeli S, Brewer M, Song G, Chatenet D . Targeting the PAC1 Receptor for Neurological and Metabolic Disorders. Curr Top Med Chem. 2019; 19(16):1399-1417. PMC: 6761004. DOI: 10.2174/1568026619666190709092647. View

15.

Moody T, Osefo N, Nuche-Berenguer B, Ridnour L, Wink D, Jensen R . Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells. J Pharmacol Exp Ther. 2012; 341(3):873-81. PMC: 3362890. DOI: 10.1124/jpet.111.190033. View

16.

Delgado M, Leceta J, Ganea D . Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. J Leukoc Biol. 2003; 73(1):155-64. DOI: 10.1189/jlb.0702372. View

17.

Maasz G, Zrinyi Z, Reglodi D, Petrovics D, Rivnyak A, Kiss T . Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian models. Dis Model Mech. 2017; 10(2):127-139. PMC: 5312006. DOI: 10.1242/dmm.027185. View

18.

Pengsart W, Kulkeaw K . An Optical and Chemiluminescence Assay for Assessing the Cytotoxicity of against Human Neurospheroids. Bioengineering (Basel). 2022; 9(7). PMC: 9312303. DOI: 10.3390/bioengineering9070330. View

19.

Valiante S, Falanga A, Cigliano L, Iachetta G, Busiello R, Marca V . Peptide gH625 enters into neuron and astrocyte cell lines and crosses the blood-brain barrier in rats. Int J Nanomedicine. 2015; 10:1885-98. PMC: 4364164. DOI: 10.2147/IJN.S77734. View

20.

Galdiero S, Falanga A, Vitiello M, Browne H, Pedone C, Galdiero M . Fusogenic domains in herpes simplex virus type 1 glycoprotein H. J Biol Chem. 2005; 280(31):28632-43. DOI: 10.1074/jbc.M505196200. View